These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8226410)

  • 1. Susceptibility of cefoxitin-resistant isolates of bacteroides to other agents including beta-lactamase inhibitor/beta-lactam combinations.
    Cherubin CE; Appleman MD
    J Antimicrob Chemother; 1993 Jul; 32(1):168-71. PubMed ID: 8226410
    [No Abstract]   [Full Text] [Related]  

  • 2. In-vitro activity of four penicillin/beta-lactamase inhibitor combinations against cefoxitin-susceptible and cefoxitin-resistant Bacteroides fragilis isolates.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1991 Feb; 27(2):243-4. PubMed ID: 2055814
    [No Abstract]   [Full Text] [Related]  

  • 3. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antimicrobial activity of old and new beta-lactams against cefoxitin-resistant Bacteroides fragilis group isolates by beta-lactamase inhibitors.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 May; 25(5):873-5. PubMed ID: 2373670
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of beta-lactamases in clinical isolates of Bacteroides.
    Eley A; Greenwood D
    J Antimicrob Chemother; 1986 Sep; 18(3):325-33. PubMed ID: 3490466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic activity of cefsulodin combined with cefoxitin and sulbactam against Bacteroides species.
    Fu KP; Kimble EF; Zoganas H; Konopka EA
    J Antimicrob Chemother; 1984 Mar; 13(3):257-65. PubMed ID: 6327598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative activity of cefsulodin against anaerobic bacteria of clinical interest: synergy with cefoxitin.
    Watt B; Brown FV
    J Antimicrob Chemother; 1981 Mar; 7(3):269-78. PubMed ID: 6974166
    [No Abstract]   [Full Text] [Related]  

  • 8. The in vitro activity of mezlocillin when combined with cefoxitin or clavulanic acid.
    Wise R; Gillett AP; Andrews JM
    J Antimicrob Chemother; 1979 May; 5(3):301-6. PubMed ID: 113377
    [No Abstract]   [Full Text] [Related]  

  • 9. Selection of cefoxitin-resistant bacteroides thetaiotaomicron mutants and mechanisms involved in beta-lactam resistance.
    Fang H; Edlund C; Nord CE; Hedberg M
    Clin Infect Dis; 2002 Sep; 35(Suppl 1):S47-53. PubMed ID: 12173108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefoxitin resistance in Bacteroides species: evidence indicating two mechanisms causing decreased susceptibility.
    Piddock LJ; Wise R
    J Antimicrob Chemother; 1987 Feb; 19(2):161-70. PubMed ID: 3571041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibilities of anaerobic gram-negative bacilli to thirteen antimicrobials and beta-lactamase inhibitor combinations.
    Hill GB; Ayers OM; Everett BQ
    J Antimicrob Chemother; 1991 Dec; 28(6):855-67. PubMed ID: 1816182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of anaerobic bacteria to beta-lactam antibiotics in the United States.
    Johnson CC
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S371-6. PubMed ID: 8324150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An investigation of beta-lactamases from clinical isolates of Bacteroides species.
    Edwards R; Greenwood D
    J Med Microbiol; 1992 Feb; 36(2):89-95. PubMed ID: 1740789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa.
    McLaughlin JC; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; Pfaller MA
    J Antimicrob Chemother; 1994 Feb; 33(2):223-30. PubMed ID: 8182003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do antimicrobial susceptibility patterns of colonic isolates of Bacteroides species change after antibiotic prophylaxis with cefoxitine during elective abdominal surgery?
    Toprak NU; Güllüoğlu BM; Cakici O; Akin ML; Demirkalem P; Celenk T; Söyletir G
    World J Surg; 2005 Oct; 29(10):1311-5. PubMed ID: 16142428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new potent beta-lactamase inhibitor, BRL 42715, with inherent activity against Bacteroides fragilis group strains.
    Aldridge KE
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S335-8. PubMed ID: 8324143
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia.
    Smith JM; Avdic E; Tamma PD; Zhang L; Carroll KC; Cosgrove SE
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5049-51. PubMed ID: 26033720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of anaerobic bacteria from the intestinal microflora of healthy children and antimicrobial-treated children in Nicaragua.
    Cáceres M; Carera E; Palmgren AC; Nord CE
    Rev Esp Quimioter; 1998 Sep; 11(3):221-8. PubMed ID: 9795308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activity of new beta-lactam antibiotics on cefoxitin-resistant strains of Bacteroides fragilis.
    Dornbusch K; Olsson-Lijequist B; Nord CE
    J Antimicrob Chemother; 1980 Mar; 6(2):207-16. PubMed ID: 6966626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.